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Abstract
Background: Depression is of significant global concern. Despite a range of effective treatment options it is
estimated that around one in five diagnosed with an acute depressive episode continue to experience enduring
symptoms for more than 2 years. There is evidence for effectiveness of individual music therapy for depression.
However, no studies have as yet looked at a group intervention within an NHS context. This study aims to assess
the feasibility of conducting a randomised controlled trial of group music therapy for patients with long-term
depression (symptom durations of 1 year or longer) within the community.
Methods: This is a single-centre randomised controlled feasibility trial of group music therapy versus wait-list
control with a nested process evaluation. Thirty participants will be randomised with unbalanced allocation (20 to
receive the intervention immediately, 10 as wait-list controls). Group music therapy will be offered three times per
week in a community centre with a focus on songwriting. Data will be collected post-intervention, 3 and 6 months
after the intervention finishes. We will examine the feasibility of recruitment processes including identifying the
number of eligible participants, participation and retention rates and the intervention in terms of testing components,
measuring adherence and estimation of the likely intervention effect. A nested process evaluation will consist of
treatment fidelity analysis, exploratory analysis of process measures and end-of-participation interviews with
participants and referring staff.
Discussion: Whilst group music therapy is an option in some community mental health settings, this will be the first
study to examine group music therapy for this particular patient group. We will assess symptoms of depression,
acceptability of the intervention and quality of life. We anticipate potential challenges in the recruitment and retention
of participants. It is unclear whether offering the intervention three times per week will be acceptable to participants,
particularly given participants’ enduring symptoms and impact upon motivation. This study will provide data to inform
both development of the intervention and to assess and inform the design of a full trial.
Trial registration: ISRCTN.com, ISRCTN18164037. Registered on 26 September 2016.
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Background
Depression is of significant global concern. The World
Health Organisation has predicted that by 2020 it will
become the second leading contributor to the global
burden of disease [1], and accounts for around 40% of
suicides by people receiving treatment for mental illness
in the UK [2]. It is estimated that between 8 and 12% of
the UK population experience depression in any year
[3], whilst around one in five diagnosed with an acute
depressive episode goes on to develop chronic depres-
sion [1]. Chronic or persistent depression is diagnosed
when the symptoms of depression endure for 2 years or
longer. The severity and course of symptoms may vary,
from milder symptoms of dysthymia to chronic major
depression [3]. For this specific patient group, the me-
dian duration can be anything between 5 and 20 years
[4, 5] and treatment is particularly difficult. Frequent
relapses can lead to pessimism and demoralisation of
both patient and professional [5], leading in turn to lack
of compliance or ‘giving up’ on treatment. Overall,
chronicity of depression is associated with increased
healthcare costs through greater use of services and
rates of hospitalisation [2, 6, 7].
Whilst the definition of chronic or persistent depres-
sion is marked by symptoms lasting 2 years or longer,
durations of 1 year or longer are clinically relevant and
may be indicative of a chronic course [8, 9]. It is
estimated that around 40% of patients with chronic
depression fulfil criteria for treatment resistance, although
further evidence suggests that many may not have
received adequate or recommended treatment [10]. Given
that treatment resistance may be identified as soon as 6
months after diagnosis (or after two trials of antidepres-
sant drugs [11]), symptoms enduring for 1 year or longer
may be considered as an indicator of both potential
chronicity and need for further intervention. There may
also be clinical benefit to offering intervention at a point
before symptoms have become long-standing. To avoid
confusion with defined criteria for chronic or persistent
depression, this study uses the term ‘long-term depression’
to define patients with symptoms of depression that have
lasted 1 year or longer.
Current treatments for long-term depression
Current recommended interventions for long-term
depression are a mixture of either pharmacological or
talking-based approaches, with mixed evidence on their
combined use. Earlier reviews have indicated that both
pharmacotherapy [12, 13] and psychotherapy [14] are
effective treatments for chronic depression. The effects
appear to be maximised when used in combination,
although around 18 sessions of psychotherapy may be
necessary in order to see clinical effects [15]. A more
recent review found limited evidence for their use in
combination [16] but suggested psychotherapy might
have a continued role in promoting and maintaining
treatment adherence, given that patient preferences are
often for psychotherapy over medication and that they
achieve wider clinical benefits (such as improving coping
strategies and quality of life). Two further reviews
[17, 18] point towards an approach for use of both in
combination, leading the European Psychiatric Association
to recommend combined treatment with a personalised
approach based on patient preferences and needs [19].
Based on current evidence, psychotherapeutic interven-
tions that target interpersonal problems (such as the cogni-
tive behavioural analysis system of psychotherapy (CBASP)
and interpersonal psychotherapy (IPT)) appear to be
indicated in addressing symptoms of chronic depression,
whilst further studies indicate that long-term psychoana-
lytic psychotherapy may also improve long-term outcomes
in treatment-resistant depression [20].
Childhood adversity and maltreatment such as abuse
and problems with the family environment have been
linked to the development and chronicity of major
depressive disorder [9, 19, 21–29]. A review of risk factors
for chronic depression suggested that along with a younger
age of onset and family history of mood disorder, problems
within the social environment (such as low social integra-
tion, low social support and negative social interaction)
were associated with chronicity of symptoms [4]. A group
approach may therefore be of utility in addressing social in-
tegration, interaction and providing emotional and social
support, and have potentially greater cost-effectiveness.
Group music therapy: evidence to date
Music therapy is a complex intervention in that it
utilises a range of components to promote health. Such
components include a therapeutic relationship, a range
of active and receptive musical activities and verbal
reflection. These are provided flexibly in response to the
individual or group and are often led by the patient.
Activities include improvisation, songwriting and use of
pre-known music, with opportunities for verbal reflec-
tion. Within the UK, music therapists are regulated by
the Health and Care Professions Council (HCPC) and
must have completed approved training to Masters level.
There is evidence to suggest the effectiveness of music
therapy for a range of mental health problems including
depression [30], schizophrenia [31, 32] and severe mental
illness [33, 34]. A meta-analysis by Gold et al., has identified
a dose-effect response, whereby symptom improvement is
associated with the number of sessions received [34]. The
analysis suggested that around 4 sessions would be required
to have a small effect on depressive symptoms, 10 for a
medium effect and 16 for a large effect. For global function-
ing this was estimated at 3 sessions for a small effect to 51
sessions for a large effect and for general symptoms, 10
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sessions for a small effect to 39 sessions for a large effect.
The impact of session frequency and duration is less clear
and within this meta-analysis [34], varied between one and
six times per week over durations of 1 to 6 months.
A Cochrane review of music therapy for depression in-
cluded only five studies, three of which were in elderly
populations, one of which was in children in schools and
one of which was in adult psychiatric inpatients [35]. As
such, these were too heterogeneous to compare in a
meta-analysis. Four of these studies reported a greater
reduction in symptoms of depression compared to
standard care, whilst one study using music therapy as
an active control found no significant change in com-
parison to standard care. The authors noted low drop-
out rates leading the authors to conclude that whilst the
intervention appears to have good acceptability, conclu-
sions could not be drawn on its effectiveness [35].
Two further randomised controlled trials have since
been published: Erkkilä et al. [30] sought to determine
the efficacy of individual music therapy for depression
compared to standard care. Music therapy consisted of
free improvisation and discussion informed by psycho-
dynamic theory, for 60 minutes, twice a week for 10
weeks. At the 3-month follow up, patients in the music
therapy group had greater improvement in depression,
anxiety and general functioning compared to the control
group. Improvements were also seen in alexithymia and
quality of life and were sustained at the 6-month follow
up, but these were not statistically significant when com-
pared to the control group. The second trial [36] looked
at the effect of group improvisational music therapy on
depression in adolescents and adults with substance
abuse. Twenty-four patients were randomly allocated to
12 sessions of music therapy plus standard care or
standard care alone. At the end of the 12 sessions, there
were significant differences between groups in observer-
rated depression but not self-rated depression, with
greater improvements in the music therapy group.
Wider randomised controlled trials of music therapy in
mental healthcare suggest it may be particularly effective in
encouraging people with low motivation and serious men-
tal disorders to attend and engage in therapy [33, 37, 38].
Notably, a study of group music therapy in the community
demonstrated improved quality of life in patients with se-
vere mental illnesses [37]. It may be that nonverbal aspects
of communication may make it easier or more acceptable
for people who find it difficult to utilise talking therapies
and may help them to re-engage with these at a later point,
as seen in a study of music therapy for post-traumatic
stress disorder [38].
Theoretical basis of the intervention
A core problem when working with chronic depression is
demoralisation of both patient and professional, leading in
turn to lack of compliance or ‘giving up’ on treatment [5].
Group music therapy may offer a very different thera-
peutic encounter compared to current treatments and has
the potential to address intrapersonal and interpersonal
domains and promote confidence and participation at a
community level. The experience of making music pro-
vides an opportunity for nonverbal expression and com-
munication, strong shared group experiences, rehearsal of
different ways of relating and opportunities to have a
sense of achievement, ‘perform’ or share different, non-
illness parts of themselves [39]. A positive experience
within a community-based music therapy group may then
place the person in contact with their musical and inner
psychological ‘resources’ [40], which may provide oppor-
tunities to build inner resources for coping and resilience
and promote hope, and can be linked to wider theories of
personal recovery in mental illness [41, 42].
Long-term depression can be understood from a var-
iety of biological, neurological, psychological, relational
and social perspectives. We believe that Seligman’s
model of learned helplessness provides the clearest start-
ing point for understanding how music therapy might
help long-term depression [43]. This theory suggests
that with ongoing aversive events, a person may perceive
increasing lack of control and helplessness. Such
repeated events lead to a downward spiral of lessening
confidence and sense of control of the situation,
reducing motivation, retreating from the environment
(thus impacting upon wider social relationships) and
thus impacting upon mood and wider functioning. In
long-term depression such experiences are manifested in
the prolonged low mood, low feelings of self-worth, hope-
lessness, lack of energy, irritability and insomnia. These
symptoms then have a wider impact upon the individual’s
emotions, cognitions, social life and wider functioning.
Erkkilä and colleagues [44] use a related theory of
withdrawal motivation [45] to explain, within the frame-
work of psychodynamic theory, how such symptoms
impact upon a person’s ability to create and symbolize -
processes that both have the ability to transform a feel-
ing state, or connect meaningfully with another person.
The use of free improvisation (a form of active music-
making) is assumed by music therapists to be something
that can be accessed by all as a means of expressing
internal states, creating and connecting with others. The
nonverbal interactions that occur within such music-
making enable a different experience of communicating
and relating to others, in a medium that has been shown
to be motivating and stimulating for people who other-
wise find it difficult to engage [33]. Such experiences
may enable opportunities for more positive social experi-
ences than those experienced verbally, and opportunities
to then verbally process these with other members of
the group. The musical attunement facilitated by the
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music therapists when making music may help partici-
pants to experience nonverbal social contact and close-
ness, and address feelings of social isolation [46]. Such a
process is implicated in building initial therapeutic trust,
which again, has been noted to be of importance for this
clinical group [44].
Consultation with patient and public groups at the
study inception suggested that the intervention should
be community-based with a strong sense of structure
and musical ‘end-product’ such as recording or perform-
ance, as this would build self-esteem and foster feelings
of achievement. Singing was frequently suggested as a
more accessible way to make music. We have therefore
incorporated a group music-therapy songwriting inter-
vention developed in Australia [37, 47] alongside princi-
ples from psychodynamic improvisational music therapy
[44] and resource-oriented music therapy [40, 48].
Studies of singing and songwriting suggest that group
singing can most powerfully invoke positive emotions,
feelings of connectedness to others and group bonding
[49–52] and act as encouragement for people to return
to and participate in groups [53]. Creating bespoke
songs as a group has the added potential for participants
to begin to find ways of verbally expressing their experi-
ences and having this supported through active group
music-making [44, 54–56].
Taken in combination, the evidence for music therapy
to address symptoms of long-term depression is promis-
ing, but to date the intervention has not been specified
or tested for its effectiveness within a UK National
Health Service (NHS) context.
Rationale for the current study
Before evaluating the effectiveness of an intervention, it
is important to assess whether implementation of the
trial methodology is feasible. This is particularly relevant
in complex interventions and settings [57–60].
Feasibility of the intervention
Whilst music therapy is commonly provided in commu-
nity mental health settings, this is the first time the inter-
vention has been tailored for this particular diagnostic
group with an emphasis on songwriting [37, 55]. It will
therefore be important to assess whether the intervention
is delivered as described in practice and to examine the
role of each component in relation to outcomes. It will
also be necessary to examine the acceptability of the inter-
vention (both in terms of how it is provided and its indi-
vidual components) to patients and music therapists, as
this will have a bearing on whether the intervention can
feasibly be delivered as described. Information on the
intervention in this pilot will be used to refine and where
necessary, adapt the current approach to ensure accept-
ability, adherence and treatment fidelity.
Feasibility of the research design
To our knowledge a randomised controlled trial of
group music therapy has not been conducted within this
set of NHS services before. The feasibility of our pro-
posed methods for identifying, recruiting and retaining
participants with chronic depression from primary care
and secondary care NHS services is not yet known.
Piloting on a small scale will enable us to determine
both the feasibility of our proposed processes and the re-
sources and approaches required [61].
Estimation and appropriateness of outcomes
We expect to see changes in a range of clinical and social
outcomes. However, we do not yet know which measures
might be most appropriate in terms of acceptability of
completion and variability of outcome. Our proposed
primary outcome is symptoms of depression, measured by
an observer-rated scale (Montgomery-Åsberg depression
rating scale [62]). We will also measure potential changes
in self-rated depression, social functioning, psychological
distress, self-esteem, self-efficacy, mood, relationships,
satisfaction with treatment, work and social adjustment,
quality of life and service use. We will examine the accept-
ability and provide descriptive statistics and estimates of
effect of the proposed outcome measures to inform the
design of a future randomised controlled trial. As we are
providing a group intervention, we also plan to estimate the
intra-cluster correlation coefficient to take this into account
in conjunction with future sample size calculations. To aid
estimation of the cost of the intervention, we plan to con-
duct a preliminary economic analysis to estimate the cost
of services received by the intervention and control groups.
Design considerations
For comparison we have chosen to use a wait-list control.
This will enable us to compare the intervention to treat-
ment as usual, with the option for those in the control
group to receive group music therapy at the study end.
We propose offering three sessions per week to
participants for a number of reasons. First, in a previous
study in a similar environment [37] there were high rates
of attrition in the once-per-week group. Our previous
research within an acute inpatient environment demon-
strated that offering an increased frequency was accept-
able, of therapeutic benefit and increased the chances of
attending a greater number of music therapy sessions
[53]. Second, given the potential difficulties in motiv-
ation and attending sessions, the increased frequency
may help to build momentum and keep attendance
going. Greater frequency also means it may be possible
to develop a greater stability of group membership,
which will help to foster trust and commitment in the
group and, in the case of ongoing songwriting and per-
formance work, provide opportunities to progress these
Carr et al. Trials  (2017) 18:149 Page 4 of 15
longer-term activities. In total, 42 sessions are available
to participants, which may enable us to detect a large ef-
fect on depressive symptoms, and medium-to-large ef-
fects on general symptoms [34].
Methods
Design
This is a single-centre, randomized controlled feasibility
trial of group music therapy versus wait-list control with
post-intervention, 3-month and 6-month post-intervention
follow up and nested process evaluation.
Aims and objectives
The study aims to pilot group music therapy for patients
with long-term depression and assess the feasibility of
conducting a larger randomised controlled trial. The
results will inform the design of future studies, the
refinement of the manual and training of music thera-
pists. Should the trial be found feasible, a protocol will
be produced for a full-scale randomised controlled trial.
The objectives are to:
1. Assess the acceptability of the methodology to
professionals and patients
2. Assess the feasibility of recruitment processes
3. Identify the number of eligible participants,
participant rates and retention rates
4. Assess the researcher time and costs per participant
5. Assess the appropriateness of outcome measures,
data on the variability of the outcome for sample
size calculation, an estimate of the control group
mean to ensure change is feasible and the
intra-cluster correlation coefficient
6. Assess the intervention in terms of testing
components, measuring adherence and estimating
the likely intervention effect
7. Assess the exact cost of delivery of group music
therapy and the services received
Setting and participants
This is a single-site study with group music therapy pro-
vided in a community location by East London NHS
Foundation Trust music therapists. Thirty participants
will be recruited from secondary care Community
Mental Health Teams (CMHTs), Improving Access to
Psychological Therapies (IAPT) services and referrals
from Participant Identification Centres (PICs) within
primary care general practice (GP) services.
Patients are eligible for study entry if they meet the
following criteria:
 Confirmed diagnosis of depression (ICD10 F31-39)
including post-schizophrenic depression (ICD10 F20.4)
and prolonged depressive reaction (ICD10 F43.21)
 Receiving pharmacological and/or psychological
treatment for 12 months or longer
 Aged 18 years or above
 Capacity to give informed consent
Patients will not be eligible if any of the following
are present:
 Diagnosis of organic mental disorder (ICD10 F00-09)
 Bipolar affective disorder - current manic episode
(ICD10 F30, F31.0, F31.2, F31.6, F31.70-F31.74)
 No capacity to give informed consent
 Risk of suicide necessitating hospitalisation
Participant identification and recruitment process
Participant identification, recruitment and follow-up
procedures are shown in Fig. 1. Recruitment will com-
mence 8 weeks before the first scheduled music therapy
group. Patient identification will be made by a member
of the patient’s existing clinical care team in the follow-
ing ways:
1. Primary care PICs: GP surgeries. All adults on
record as meeting the inclusion criteria will be
identified by an administrator working within the
service. The researcher will provide a letter of
invitation which will be sent out with an
information sheet. Those expressing interest will be
invited to speak with the researcher for further
information.
2. Talking therapies (IAPT) service and CMHTs.
Patients meeting the inclusion criteria will be
informed of the study and provided with an
information sheet by the healthcare professional
overseeing their care. Assent will be gained for the
professional to put the patient in touch with the
researcher. Where possible, a researcher will be
based on site to speak with patients to minimise
further additional visits.
Interested participants will meet with a member of the
research team to go through the study information and
answer any questions. Inclusion and exclusion criteria
will be confirmed along with assessment of mental cap-
acity. Written informed consent will be taken a mini-
mum of 24 hours later along with baseline assessments.
Participants are informed they are free to withdraw at
any time without giving reasons and without prejudicing
any further treatment.
Intervention
The intervention has been described in full in a manual
developed for the purposes of this study and has been in-
formed by existing manuals for group songwriting [44],
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individual psychodynamic music therapy for depres-
sion [30, 47] and principles of resource-oriented music
therapy [48]. The intervention was developed through
focus group discussions with music therapists, psycholo-
gists and service users with a diagnosis of depression and
was finalised in team discussions with music therapists
and Heads of Arts Therapies involved in the study. The
Template for Intervention Description and Replication
[63] and Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) [64] checklists are attached
as Additional files 1 and 2. The intervention manual and
full study protocol are available on request from the
authors.
Group music therapy will be provided three times per
week over 14 weeks by two HCPC-registered music
therapists. Each session will last 90 minutes and will
comprise warm-up activities moving to sharing of pre-
known songs and improvisation. Therapists will move
from improvisation into songwriting, which will then be
the main focus for the remainder of the session.
Fig. 1 Flow diagram of the SYNCHRONY study to assess the feasibility of group music therapy for chronic depression. BDI-II Beck Depression
Inventory-II, CSO Clinical Studies Officers, GP general practice, IAPT Improving Access to Psychological Therapies, MADRS Montgomery-Åsberg
Depression Rating Scale, MT Music Therapists, PICs Participant Identification Centres, RA Research Assistant, SU-R Service-User Researcher
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Opportunities will be offered after each activity for ver-
bal reflection. The last 15 minutes will be dedicated to
reviewing the session and may include playing through a
final piece of music.
The intervention will be provided in a community
centre within the locality of Newham. The community
centre is a non-NHS site and offers facilities for
additional social contact such as a café and wider non-
medical community groups. Music therapists will receive
weekly clinical supervision from the chief investigator.
Wait-list control
The wait-list control group will receive treatment as usual
whilst study measures are completed and will then be eli-
gible to receive group music therapy once the 6-month
follow up has been completed. Receipt of services will be
assessed throughout this time in both arms to enable an
initial description of the types of services received and as-
sociated cost.
Criteria for discontinuation
Participants will be withdrawn from the intervention if
the participant becomes too unwell to continue due to
loss of capacity to consent to group attendance, if the
patient has a level of risk assessed by the clinical team to
require hospitalisation or if music therapists and the
clinical team determine that the patient’s current mental
state, behaviour or risk to self or others requires discon-
tinuation of the intervention. Reasons for withdrawal
will be documented as part of feasibility measures.
Randomisation
Randomisation will occur once all 30 participants have
been recruited and baseline measures have been com-
pleted. In order to obtain sufficient data on the interven-
tion, we will utilise simple block randomisation with
unbalanced allocation so that 20 participants receive the
intervention and 10 are allocated to the wait-list control
group. A researcher independent of the study team will
perform the randomisation using the Experimental Design
Generator and Randomiser (EDGAR-II) [65] and inform
the music therapists and unblinded member of the study
team of the allocation by email. The music therapists will
then inform participants of their allocation and provide
additional support if required.
Blinding
Blinding of participants and therapists is not possible due
to the study intervention and timing of assessments. Re-
searchers conducting follow-up assessments will be blind
to participant allocation. An independent statistician will
conduct the initial analysis of the main outcomes Due to
the unbalanced design it will not be possible to blind the
statistician to the treatment allocation.
Outcome measures and endpoints
Our primary interest is in the feasibility of the trial de-
sign and intervention. A summary of the main feasibility
outcomes, success criteria and timing is shown in
Table 1. Proposed clinical outcomes are:
Observer rated:
1. Symptoms of depression as measured by the
Montgomery-Åsberg Depression Rating Scale
(MADRS) [62, 66, 67]
2. Social functioning as measured by the life skills
profile (LSP) [68]
3. Level of hospitalisation as measured by admission,
length of stay and number of readmissions
Self-report:
4. Self-reported symptoms of depression as measured
by the Beck Depression Inventory II (BDI-II) [69–71]
5. Psychological distress as measured by the Brief
Symptom Inventory (BSI) [72]
6. Self-esteem as measured by the Rosenberg
Self-Esteem Scale (RSES) [73–75]
7. Perceived self-efficacy as measured by the General
Perceived Self-Efficacy Scale (GPSES) [76–78]
8. Satisfaction with treatment in community services
as measured by the Client Satisfaction
Questionnaire (CSQ) [79]
9. Work and social adjustment as measured by the
Work and Social Adjustment Scale (WSAS) [80]
10. Quality of life as measured by the Manchester
Short Quality of Life Scale (MANSA) [81, 82]
11. Receipt of services as measured by the Client
Services Receipt Inventory (CSRI) [83, 84]
Our proposed clinical endpoint is the week post-
intervention, with secondary endpoints at 3 and 6 months
post-intervention. Process measures of attendance, self-
reported depression symptoms (BDI-II [69]) at weeks 3, 6
and 9 and weekly mood pre-session and post-session
(Dispositional Mood Scale (DMS) [85, 86]) and group
relationships (Relationship Satisfaction Scale (RSS) [87])
will be measured.
Data collection
A schedule of data collection is shown in the SPIRIT dia-
gram in Fig. 2 [64]. Inter-rater training was conducted for
observer-rated measures prior to recruitment. Inter-rater
reliability between researchers for the MADRS was high
(ICC = .995 (p < .001), 95% CI .987 to .999).
Baseline assessments will occur as soon as possible
after informed consent is obtained. Follow-up visits will
be arranged in the week following the end of the inter-
vention, and at 3 and 6 months after the intervention
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end. Participants in the intervention arm will each re-
ceive a payment of £10 to contribute towards travel
costs and participants in the wait-list control group
will each receive £15 in the form of shopping
vouchers. Participants will be eligible to receive
assistance with the cost of transport to and from
therapy sessions if they currently do not receive such
help.
Researchers conducting blind follow-up assessments
will enter the data onto paper case report forms de-
signed for each assessment. These will be transferred
into an electronic database and double-entered. Limits
are set on data values to be entered to ensure only valid
entries are permitted.
Nested process evaluation
We will conduct a process evaluation with the follow-
ing aims:
1. To understand exactly how the intervention
was delivered in practice (treatment fidelity
analysis)
2. Describe processes of attendance and hypothesised
process factors of self-reported depression, mood
and group relationships from week to week
3. Understand subjective experiences and attributions
for change of the intervention from the
perspective of patients, music therapists and
referring staff
Fig. 2 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) diagram of assessments at enrolment, allocation, 3-weekly
sessions, post-intervention, 3-month and 6-month time points. aAdministered in the intervention group only. bRated pre-session and post-session.
BDI-II Beck Depression Inventory-II, CSQ Client Satisfaction Questionnaire, CSRI Client Services Receipt Inventory, DMS Dimensional Mood Scale,
GPSES General Perceived Self-efficacy Scale, IIM Interest in Music Scale [95], LSP Life Skills Profile, MADRS Montgomery-Åsberg Depression Rating
Scale, MANSA Manchester Short Quality of Life Scale, RSES Rosenberg Self-esteem Scale, RSS Relationship Satisfaction Scale, WSAS Work and Social
Adjustment Scale
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4. Compare reported quantitative and qualitative
processes against the proposed logic model and to
revise accordingly
The process evaluation will employ an embedded mixed
methods design and will consist of data collection of video
data of the intervention itself, client self-reported mea-
sures (weekly quantitative process measures of mood pre-
session and post-session (DMS [86]), group relationships
pre-session and post-session (RSS) [87]) and qualitative
end interviews 1 month post-intervention. The interview
is optional for service users but we aim to conduct a mini-
mum of 12 interviews.
Quantitative analysis will provide a descriptive analysis
of the course of weekly process measures. We will
descriptively explore whether there are any differences
between compliant and non-compliant attenders, re-
sponders and non-responders and whether any socio-
demographic and clinical characteristics are associated
with outcomes.
Qualitative evaluation will comprise end-of-study
interviews with 12 participants, their referring staff and
music therapists. Whilst interviews will have a compo-
nent to focus upon experiences of the research and
views on the design, a second part will ask for views on
the experience of the group music therapy itself. These
questions are based upon a pre-existing semi-structured
interview (Client Change Interview [88, 89]) to elicit
clients’ views of and attributions for change. We have
adapted this interview for music therapists and referring
clinicians to also reflect upon possible observed changes
in the participants who they have worked with and their
views of the intervention.
Interviews will be transcribed and imported into
NVivo qualitative analysis software and read a number
of times by members of the research team. Members will
individually code 25% of the interviews and then meet to
decide upon a preliminary thematic frame. As interviews
will be asking about individual experiences, coding will
take a phenomenological perspective and seek to retain
the essence of individual narratives. The team will con-
tinue to code and meet regularly to discuss the adequacy
of the frame in reflecting individual experiences. Once a
final thematic frame is agreed, we will then explore rela-
tionships between the themes identified in the data and
quantitative findings. Quantitative and qualitative data
will be compared against the hypothesised logic model
for our intervention. We will then refine and revise the
logic model based upon these findings.
Sample size
This study aims to assess the feasibility of recruitment
processes including the number of eligible participants
and participation/retention rates. Papers considering
sample size for feasibility and pilot studies suggest the
inclusion of upwards of 24–50 participants [59, 90, 91].
The present study aims to recruit 30 patients to
participate in three groups of 10 patients each. In
order to obtain sufficient data on the intervention,
randomisation will be imbalanced so that 20 are
randomised to the treatment arm and 10 to the
wait-list control group.
Studies of wider psychosocial and psychotherapeutic
interventions for chronic depression show participation
rates in the range of 25–33% of eligible patients consent-
ing to participate in the study [92–94]. With a sample
size of 30, we will be able to estimate a participation rate
of 25% to within a 95% confidence interval of +/-15%.
Assuming that one fifth of patients accessing primary
care for depression will have developed chronic depres-
sion, we estimate approximately 1300 patients within
primary care will be eligible for this study. We estimate
each practice will have around 100 patients with depres-
sion, of which around 20 will have enduring symptoms.
Within the secondary care sites in which we plan to
recruit, there are currently around 1960 patients with a
diagnosis of depression. Assuming that one fifth will
have developed chronic depression [1], we estimate
approximately 392 patients within secondary care will be
eligible for this study. Based on a participation rate of
25%, we plan to approach 128 patients with the aim of
recruiting 4 per week, over 8 weeks.
Statistical analysis
Feasibility
As this is a feasibility study, the main statistical reporting
will comprise descriptive statistics and calculation of ef-
fect sizes. We will assess:
– • Acceptability of methodology to professionals and
patients through interviews via recruitment rates,
compliance, end interviews
– • Feasibility of recruitment processes
– • Deviation around specific post-intervention, and 3-
month and 6 month post-intervention follow-up as-
sessment dates for actual data collection
– • Number of eligible participants, participation rates
and retention rates
– • Researcher time and costs per participant
– • Appropriateness of outcome measures
Descriptive analyses will establish recruitment and
drop-out rates and the distribution of baseline character-
istics and all outcomes post-intervention, and 3 months
and 6 months post-intervention. The research team will
reflect upon the representativeness of the demographics
in terms of the general population of patients that could
potentially be useful in assessing the intervention.
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Recruitment and drop-out rates will be monitored on
a monthly basis allowing for examination and reporting
of patterns and whether there are any obvious trends.
This may inform the choice of the primary outcome for
a full-scale trial allowing for drop-outs in a sample-size
calculation.
Clinical outcomes
This study will employ intention-to-treat analysis. Data
from all subjects will be included in the analysis as ran-
domised. Adverse events will be reported by sub-groups
of those who were currently receiving the intervention
and those who were not.
We will first calculate a mean value of the outcome
for each unit and present them with confidence inter-
vals. Outcomes will be compared between intervention
and control groups using linear regression models,
adjusting for the baseline score of the given outcome.
The confidence limits of each treatment effect and
knowledge of the clinically important difference (where
this is available) will be used to determine whether clin-
ically important differences are ruled out by these confi-
dence limits. The intra-cluster correlation coefficient
will be calculated. Due to the small sample size, this
estimate is likely to be imprecise, therefore we will also
use estimates in the literature from similar studies for
comparison to inform the design of any future studies.
We will descriptively explore in sub-group analyses
whether there are any differences between compliant and
non-compliant attenders, responders and non-responders
and whether any socio-demographic and clinical charac-
teristics are associated with outcomes. As a preliminary
economic evaluation, we will calculate the cost of delivery
of music therapy and cost of services received by both
groups using the CSRI [83]. This will be descriptive only
to provide an estimate for future studies.
Ethical and Health Research Authority approval
This study was reviewed and received a favourable
ethical opinion by Wales Research Ethics Committee
(REC) 2 on 13 September 2016 (Reference: 16/WA/0248)
and host site approval was received from East London
Foundation NHS Trust R&D office, via Noclor on
27.09.2016. All information collected will be kept confi-
dential, stored securely and archived in accordance with
the research governance policy of the sponsor. Participant
anonymity will be retained by allocating a unique identifi-
cation number for the trial and any identifiable informa-
tion stored separately from this.
Trial governance, monitoring and auditing
The Trial Management Group (TMG) consists of the
chief investigator, study team and co-investigators and
will provide overall management of the study including
set-up, training, recruitment, promotion of the study
and interpretation of results. Given the small and explora-
tory nature of the trial, no interim analysis is planned.
Further to consultation with the study sponsor, the team
considers that the nature of the intervention does not pose
a significant risk to the study participants, and therefore
we will not use a data monitoring committee. An
Independent Advisory Panel (IAP) consisting of two inde-
pendent members will monitor the conduct of the trial
and meet four times over the course of the study to dis-
cuss research progress according to defined milestones,
emerging difficulties and dissemination of results.
The chief investigator in liaison with the sponsor and
the IAP has ultimate authority to halt the study or
withdraw individual participants should concerns arise
during the study. Adverse events will be monitored and
recorded throughout. All serious adverse events will be
reported to the sponsor and reported to the REC if
assessed to be serious, related to the study and unex-
pected. Adherence to the protocol and any subsequent
amendments will be supervised by the sponsor. Access
to data will be granted to authorised representatives
from the sponsor, host institution and the regulatory
authorities, to permit trial-related monitoring, audits
and inspections.
Ancillary and post-study care
The music therapists and researchers will maintain con-
tact with the participants’ clinical care teams throughout
the study and immediately raise any areas of concern or
need. Participants will be offered time to speak with
music therapists at the end of the intervention and will
be provided with information on music therapy groups
and wider music-making opportunities available in the
community.
Discussion
The burden of depression upon society is well-
recognised, both in human emotional and economic
costs. For those suffering from chronic depression, op-
tions for treatment are few for a condition that can last
approximately 5 to 20 years [4, 10]. Current evidence on
music therapy in mental health suggests it may be an
acceptable and tolerable intervention, which may offer a
different experience from currently recommended treat-
ment. However, there is no evidence on the effectiveness
and cost-effectiveness of such an intervention within an
NHS community context.
Building evidence for a complex intervention, such as
music therapy, requires more than just an adequate trial
design. The intervention requires a clear definition and
model, and may require subsequent steps to refine this
once examined in practice [57]. Wider research into
music therapy has pointed to the importance of training
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of therapists in the research and intervention procedures
[60]. This study will examine not only the practicalities
of trial design (in terms of recruitment strategy, reten-
tion and outcome measurement) but will also provide a
platform upon which the intervention can be specified
for the particular needs of patients with long-term de-
pression. Such findings can be immediately integrated
and applied in wider music-therapy community mental
health work.
Whilst we believe that the intervention may be appeal-
ing for those with long-term depression, we anticipate
challenges in both maintaining attendance and retaining
participants within the study. Measures to address this
include assistance with transport costs and maintaining
regular contact with participants. Whilst participants
may have access to around 42 sessions, this will occur in
a relatively short time frame of 14 weeks and it remains
to be seen whether changes can be detected within our
proposed measures.
Trial status
The SYNCHRONY study began recruitment on 27
September 2016 with the intervention planned to start
mid to late November 2016. The study will be a first step
towards refining and testing the effectiveness and cost-
effectiveness of group music therapy for long-term
depression. Whilst the study is limited in its small scale
and single locality, outcomes will contribute to a better
understanding of how best to provide music therapy for
this patient population and will enable realistic and feas-
ible plans to be made for a future large-scale trial.
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